Pipeline

MIND001 - Intravenous formulation of N,N-Dimethyltrptamine to treat Treament Resistant Depression
MIND002 - Oral Psilocybin formulation to treat headache disorders- Migraine and Cluster Headaches

1 MIND is licensing clinical stage asset (phase1/2a completed) and will initiate Phase 2b
2 MIND can license, clinical stage, once clinical stage asset reaches maturity (presently enrolling for Phase1/2a)
3 MIND is licensing clinical stage asset (phase1/2a completed) and will initiate Phase 2b
4 We will develop formulations of DMT which will have therapeutic effect without accompanying psychedelic effect, that will allow at-home, more economical and scalable paradigms
*Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects Am J Psychiatry 180:5, May 2023